Assessing and Treating Patients With Increasing Prostate Specific Antigen Following Radical Prostatectomy

Journal of Urology

Volumn 178, Issue 3 SUPPL., 2007, Pages

  Sandler, Howard M ^a   Eisenberger, Mario A ^b  

^a UNIVERSITY OF MICHIGAN   (United States)

^b JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

prostate; prostatic neoplasms; prostatic specific antigen; radiotherapy

Indexed keywords

ANTIANDROGEN; BICALUTAMIDE; PLACEBO; PROSTATE SPECIFIC ANTIGEN;

ADULT; ANDROGEN DEPRIVATION THERAPY; ARTICLE; CANCER HORMONE THERAPY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER STAGING; CANCER SURVIVAL; CLINICAL PRACTICE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE COURSE; GLEASON SCORE; HUMAN; MAJOR CLINICAL STUDY; MALE; METASTASIS; MORBIDITY; ONCOLOGY; PATIENT MONITORING; POSTOPERATIVE PERIOD; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; RANDOMIZED CONTROLLED TRIAL; TREATMENT FAILURE; TREATMENT OUTCOME;

COMBINED MODALITY THERAPY; DISEASE PROGRESSION; HUMANS; MALE; NEOPLASM METASTASIS; NEOPLASM RECURRENCE, LOCAL; PROSTATE-SPECIFIC ANTIGEN; PROSTATECTOMY; PROSTATIC NEOPLASMS;

EID: 34547655304     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.juro.2007.04.034     Document Type: Article

References (21)

1. Miller D.C., Gruber S.B., Hollenbeck B.K., Montie J.E., and Wei J.T. Incidence of initial local therapy among men with lower-risk prostate cancer in the United States. J Natl Cancer Inst 98 (2006) 1134
2. Stephenson A.J., Scardino P.T., Eastham J.A., Bianco Jr. F.J., Dotan Z., Fearn P.A., et al. Preoperative nomogram predicting the 10-year probability of prostate cancer recurrence after radical prostatectomy. J Natl Cancer Inst 17 (2006) 715
3. Amling C.L., Blute M.L., Bergstralh E.J., Seay T.M., Slezak J., and Zincke H. Long-term hazard of progression after radical prostatectomy for clinically localized prostate cancer: continued risk of biochemical failure after 5 years. J Urol 164 (2000) 101
4. Amling C.L., Bergstralh E.J., Blute M.L., Slezak J.M., and Zincke H. Defining prostate specific antigen progression after radical prostatectomy: what is the most appropriate cut point?. J Urol 165 (2001) 1146
5. Stephenson A.J., Kattan M.W., Eastham J.A., Dotan Z.A., Bianco Jr. F.J., Lilja H., et al. Defining biochemical recurrence of prostate cancer after radical prostatectomy: a proposal for a standardized definition. J Clin Oncol 24 (2006) 3973
6. Pantuck A.J., Leppert J.T., Zomorodian N., Aronson W., Hong J., Barnard R.J., et al. Phase II study of pomegranate juice for men with rising prostate-specific antigen following surgery or radiation for prostate cancer. Clin Cancer Res 12 (2006) 4018
7. Kane C.J., Amling C.L., Johnstone P.A., Pak N., Lance R.S., Thrasher J.B., et al. Limited value of bone scintigraphy and computed tomography in assessing biochemical failure after radical prostatectomy. Urology 61 (2003) 607
8. Cher M.L., Bianco Jr. F.J., Lam J.S., Davis L.P., Grignon D.J., Sakr W.A., et al. Limited role of radionuclide bone scintigraphy in patients with prostate specific antigen elevations after radical prostatectomy. J Urol 160 (1998) 1387
9. Proano J.M., Sodee D.B., Resnick M.I., and Einstein D.B. The impact of a negative (111)indium-capromab pendetide scan before salvage radiotherapy. J Urol 175 (2006) 1668
10. Partin A.W., Pearson J.D., Landis P.K., Carter H.B., Pound C.R., Clemens J.Q., et al. Evaluation of serum prostate-specific antigen velocity after radical prostatectomy to distinguish local recurrence from distant metastases. Urology 43 (1994) 649
11. Stephenson A.J., Shariat S.F., Zelefsky M.J., Kattan M.W., Butler E.B., The B.S., et al. Salvage radiotherapy for recurrent prostate cancer after radical prostatectomy. JAMA 291 (2004) 1325
12. Pound C.R., Partin A.W., Eisenberger M.A., Chan D.W., Pearson J.D., and Walsh P.C. Natural history of progression after PSA elevation following radical prostatectomy. JAMA 281 (1999) 1591
13. Eisenberger M.A., Partin A.W., Pound C., Roostelaar C.V., Epstein J., and Walsh P. Natural history of progression in patients with biochemical (PSA) relapse following radical prostatectomy: update. Proc Am Soc Clin Oncol 22 (2003) Abstract 1527
14. Freedland S.J., Humphreys E.B., Mangold L.A., Eisenberger M., Dorey F.J., Walsh P.C., et al. Risk of prostate cancer-specific mortality following biochemical recurrence after radical prostatectomy. JAMA 294 (2005) 433
15. D'Amico A.V., Moul J.W., Carroll P.R., Sun L., Lubeck D., and Chen M.H. Surrogate end point for prostate cancer-specific mortality after radical prostatectomy or radiation therapy. J Natl Cancer Inst 95 (2003) 1376
16. Mehta S.S., Lubeck D.P., Sadetsky N., Pasta D.J., and Carroll P.R. Patterns of secondary cancer treatment for biochemical failure following radical prostatectomy: data from CaPSURE. J Urol 171 (2004) 215
17. Stephenson A.J., Pollack A., Kattan M.W., and Scardino P.T. Post-prostatectomy Radiotherapy Consortium. Proc Am Soc Clin Oncol 24 (2006) Abstract 4514
18. Feng M., Hanlon A.L., Pisansky T.M., Kuban D.A., Catton C., Michalski J.M., et al. Predictive factors for late genitourinary and gastrointestinal toxicity in patients with prostate cancer treated with adjuvant or salvage radiotherapy. Int J Radiat Oncol Biol Phys 63 (2005) S127
19. Pilepich M.V., Winter K., Lawton C.A., Krisch R.E., Wolkov H.B., Movsas B., et al. Androgen suppression adjuvant to definitive radiotherapy in prostate carcinoma-long-term results of phase III RTOG 85-31. Int J Radiat Oncol Biol Phys 61 (2005) 1285
20. Roach III M., DeSilvio M., Valicenti R., Grignon D., Asbell S.O., Lawton C., et al. Whole-pelvis, "mini-pelvis," or prostate-only external beam radiotherapy after neoadjuvant and concurrent hormonal therapy in patients treated in the Radiation Therapy Oncology Group 9413 trial. Int J Radiat Oncol Biol Phys 66 (2006) 647
21. Freedland S.J., Humphreys E.B., Mangold L.A., Eisenberger M., George D.J., and Partin A.W. Public health impact of PSA doubling time after radical prostatectomy on prostate cancer specific and overall survival. Proc Am Soc Clin Oncol 24 (2006) Abstract 4568